Silvia Mccoll Wealth Management LLC Makes New Investment in Cencora, Inc. (NYSE:COR)

Silvia Mccoll Wealth Management LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 888 shares of the company's stock, valued at approximately $247,000.

Several other hedge funds also recently made changes to their positions in the business. JFS Wealth Advisors LLC grew its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new position in shares of Cencora in the fourth quarter valued at $29,000. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the fourth quarter valued at $30,000. Kentucky Trust Co bought a new position in shares of Cencora in the fourth quarter valued at $33,000. Finally, WASHINGTON TRUST Co grew its stake in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Robert W. Baird lifted their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Citigroup lifted their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $301.18.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This trade represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,223 shares of company stock valued at $12,369,767 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

Shares of COR traded up $0.80 during midday trading on Friday, reaching $291.49. 3,890,003 shares of the stock were exchanged, compared to its average volume of 1,537,835. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market cap of $56.50 billion, a P/E ratio of 41.46, a PEG ratio of 1.31 and a beta of 0.60. The stock's 50 day simple moving average is $284.83 and its 200 day simple moving average is $258.61.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter last year, the firm earned $3.80 earnings per share. The company's revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.